RSS

Praluent

The US Food and Drug Administration (FDA) has accepted a supplemental biologics licence application (sBLA) for Praluent (alirocumab) injection as a potential treatment to reduce major adverse cardiovascular events. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Plans have been announced by Sanofi and Regeneron to make Praluent (alirocumab) more accessible and affordable for those patients with the greatest health risk and unmet need. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Sanofi and Regeneron Pharmaceuticals have announced positive results from two Phase IIIb/IV ODYSSEY-DM trials evaluating Praluent (alirocumab) in patients with diabetes and hypercholesterolemia. more

News

Sanofi and Regeneron Pharmaceuticals have completed enrollment in the global phase three, Odyssey Outcomes trial for patients suffering from acute coronary syndrome (ACS) more

News

France's Sanofi and US partner Regeneron Pharmaceuticals have reported that the phase 3 trial of drug Praluent reduced cholesterol in 69% of Japanese patients in a phase 3 trial. more

News